Abstract: Objective To find the evidence of evidence -based pharmacy to solve the problem of clinical use of meropenem, and at the same time, to explore the improvement of the meropenem infusion. Methods We searched the VIP Database, Wanfang Database, Knowledge Database, Chinese Biomedical Literature Database, Dutch EMBASE, Chinese Biomedical Literature Database and Chinese Science Citation Index Expanded Version, found the relevant reports and randomized controlled trials published in the literatures, conducted quality of liver function during the process. evaluation on the Results , and then modified the therapeutic regimen of inpatients to observe the effectiveness. Results Three randomized controlled trials on meropenem and imipenem clinical use safety showed that the main adverse reactions of meropenem included liver enzyme increase, nausea, vomiting, diarrhea and skin rash, and liver damage incidence was slightly higher than that of imipene, but the difference was not statistically significant, and the incidence of adverse reactions was not associated with dose. Two randomized controlled trials on meropenem infusion showed that 1g or 2g meropenem intravenous infusion by infusion pump for 3h could increase the antibacterial effect. Based on the above evidences, good Results were achieved in the clinical practice of this study. Conclusion For the refractory drug-resistance bacteria, 3h continuous intravenous infusion of meropenem can improve the therapeutic effect, but attention should be paid on the monitoring

Key words: evidence-based pharmacy, meropenem, imipenem